Arcellx, Inc. ACLX NASDAQ

Arcellx, Inc. (ACLX) reported total assets of $603.99M and total liabilities of $201.64M for fiscal year 2025, resulting in total equity of $402.35M.

The company held $450.33M in cash and short-term investments. Total debt stood at $96.26M, with net debt of $16M. The Debt-to-Equity (D/E) ratio was 0.24 (conservative).

Current ratio is 4.44, indicating strong short-term liquidity. Interest coverage is -10.5x (weak).

Criteria supported by this page:

• HEALTH (67/100, Partial) — some metrics are adequate but not all reach ideal thresholds
• MOAT (47/100) — Total assets $603.99M and equity $402.35M support the company's competitive scale
• VALUE (57/100) — Debt-to-Equity 0.24 contributes to the overall valuation risk assessment

Overall SharesGrow Score: 32/100 with 0/7 criteria passed.

NUVL

Nuvalent, Inc.

$105.02

+1.28%

DAWN

Day One Biopharmaceuticals, Inc.

$21.46

-0.14%

AMLX

Amylyx Pharmaceuticals, Inc.

$16.92

+2.73%

VTYX

Ventyx Biosciences, Inc.

$14.00

+0.00%

BMEA

Biomea Fusion, Inc.

$1.95

+3.72%

LLY

Eli Lilly and Company

$922.50

-0.76%

JNJ

Johnson & Johnson

$240.10

+0.90%

ABBV

AbbVie Inc.

$210.32

+1.86%